IPO registrations (S-1, F-1) · Registrants
Tonix Pharmaceuticals Holding Corp.
- SEC CIK
- 1430306 · filings on EDGAR ↗
- Former names
- TAMANDARE EXPLORATIONS INC. (2008–2011)
- Registration
- Form S-1, first filed 2008-04-09, last 2020-02-06; 11 initial registrations, 20 amendments
- Outcome
- Final prospectus filed 2018-12-10; declared effective 2008-04-18; withdrawal requested 2017-09-15
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- NV
- Business address
- 200 CONNELL DRIVE, SUITE 3100, Berkeley Heights, NJ 07922
- EIN
- 26-1434750
- Ticker
- TNXP (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Tonix Pharmaceuticals Holding Corp. on the corporate pages
Offering terms
- Final price
- $3.50 per share (424B4 filed 2018-12-10)
- Shares sold
- 861,710
- Gross proceeds
- $3,015,985 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol TNXP
- Lead underwriters
- A.G.P./Alliance Global Partners
- Syndicate
- Dawson James; Securities, Inc
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: TONIX PHARMACEUTICALS HOLDING CORP. Fuzzy (name and state)
- Form 5500 plan sponsor: TONIX PHARMACEUTICALS HOLDING CORP. EXACT (EIN (EXACT))
- Form D issuer: Tonix Pharmaceuticals Holding Corp. EXACT (CIK (EXACT))
- Lobbying client: TONIX PHARMACEUTICALS HOLDING CORP. Fuzzy (name and state)
- SEC filer: TAMANDARE EXPLORATIONS INC. EXACT (CIK (EXACT))
- Person page: David J Moss Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer,TenPercentOwner))
- Person page: Donald W Landry Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Richard H Bagger Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 55
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2008-04-09 | S-1 | S-1 (registration) | TAMANDARE EXPLORATIONS INC. | 0001165527-08-000188 ↗ |
| 2008-04-18 | EFFECT | EFFECT (declared effective) | TAMANDARE EXPLORATIONS INC. | 9999999995-08-001123 ↗ |
| 2012-04-26 | S-1 | S-1 (registration) | Tonix Pharmaceuticals Holding Corp. | 0001144204-12-023973 ↗ |
| 2012-06-04 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001144204-12-033044 ↗ |
| 2012-06-06 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-12-001737 ↗ |
| 2013-01-25 | S-1 | S-1 (registration) | Tonix Pharmaceuticals Holding Corp. | 0001144204-13-004082 ↗ |
| 2013-03-22 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001144204-13-016787 ↗ |
| 2013-04-02 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001144204-13-019627 ↗ |
| 2013-04-05 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-13-000898 ↗ |
| 2013-05-10 | S-1 | S-1 (registration) | Tonix Pharmaceuticals Holding Corp. | 0001144204-13-028032 ↗ |
| 2013-06-06 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001144204-13-033676 ↗ |
| 2013-06-20 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001144204-13-035795 ↗ |
| 2013-06-21 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001144204-13-036153 ↗ |
| 2013-07-02 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001144204-13-037798 ↗ |
| 2013-07-31 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001144204-13-042075 ↗ |
| 2013-08-08 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001144204-13-044008 ↗ |
| 2013-08-08 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-13-002353 ↗ |
| 2014-01-08 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-14-000070 ↗ |
| 2014-04-23 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-14-001087 ↗ |
| 2014-04-23 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-14-001088 ↗ |
| 2014-08-15 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-14-002533 ↗ |
| 2017-09-15 | RW | RW (withdrawal request) | Tonix Pharmaceuticals Holding Corp. | 0001615774-17-005129 ↗ |
| 2017-09-29 | S-1 | S-1 (registration) | Tonix Pharmaceuticals Holding Corp. | 0001615774-17-005489 ↗ |
| 2017-10-12 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-17-002671 ↗ |
| 2018-05-16 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-18-001273 ↗ |
| 2018-09-07 | S-1 | S-1 (registration) | Tonix Pharmaceuticals Holding Corp. | 0001615774-18-009355 ↗ |
| 2018-10-24 | S-1 | S-1 (registration) | Tonix Pharmaceuticals Holding Corp. | 0001615774-18-011280 ↗ |
| 2018-11-02 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001615774-18-011996 ↗ |
| 2018-11-05 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-18-002804 ↗ |
| 2018-12-03 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001615774-18-013697 ↗ |
| 2018-12-03 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001615774-18-013717 ↗ |
| 2018-12-06 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001615774-18-013865 ↗ |
| 2018-12-07 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-18-003062 ↗ |
| 2018-12-10 | 424B4 | 424B4 (final prospectus) | Tonix Pharmaceuticals Holding Corp. | 0001615774-18-014150 ↗ |
| 2019-06-19 | S-1 | S-1 (registration) | Tonix Pharmaceuticals Holding Corp. | 0001387131-19-004490 ↗ |
| 2019-07-01 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001387131-19-004759 ↗ |
| 2019-07-11 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001387131-19-004970 ↗ |
| 2019-07-15 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001387131-19-005027 ↗ |
| 2019-07-15 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-19-001601 ↗ |
| 2019-07-16 | 424B4 | 424B4 (final prospectus) | Tonix Pharmaceuticals Holding Corp. | 0001387131-19-005112 ↗ |
| 2019-08-23 | S-1 | S-1 (registration) | Tonix Pharmaceuticals Holding Corp. | 0001387131-19-006373 ↗ |
| 2019-09-06 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001387131-19-006791 ↗ |
| 2019-09-11 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-19-002067 ↗ |
| 2019-10-18 | S-1 | S-1 (registration) | Tonix Pharmaceuticals Holding Corp. | 0001387131-19-007745 ↗ |
| 2019-11-14 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001387131-19-008666 ↗ |
| 2019-11-14 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001387131-19-008761 ↗ |
| 2019-11-14 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-19-002571 ↗ |
| 2019-11-18 | 424B4 | 424B4 (final prospectus) | Tonix Pharmaceuticals Holding Corp. | 0001387131-19-008844 ↗ |
| 2020-01-21 | S-1 | S-1 (registration) | Tonix Pharmaceuticals Holding Corp. | 0001387131-20-000350 ↗ |
| 2020-02-06 | S-1/A | S-1/A (amendment) | Tonix Pharmaceuticals Holding Corp. | 0001387131-20-001063 ↗ |
| 2020-02-06 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-20-000276 ↗ |
| 2020-02-11 | 424B4 | 424B4 (final prospectus) | Tonix Pharmaceuticals Holding Corp. | 0001387131-20-001265 ↗ |
| 2020-04-17 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-20-000785 ↗ |
| 2021-01-04 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-21-000028 ↗ |
| 2021-05-05 | EFFECT | EFFECT (declared effective) | Tonix Pharmaceuticals Holding Corp. | 9999999995-21-001798 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-12-06 | S-1/A | registration statement | $139.42 | 2,132,701 | $297,341,173 | Nasdaq TNXP | 3 | primary document; price line, shares headline, proceeds computed, cover names 3 | document ↗ | |
| 2018-12-10 | 424B4 | final prospectus | $3.50 | 861,710 | $3,015,985 | Nasdaq TNXP | 3 | primary document; price sentence, shares headline, proceeds computed, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Moss David J | Director,Officer,TenPercentOwner | PRES, CEO, TRES, CFO, SECR | 2 | 2010–2011 | person page Fuzzy |
| DAUGHERTY BRUCE | Officer | See remarks; See Remarks; SEE REMARKS | 15 | 2013–2016 | |
| DAVIDSON STUART | Director | 10 | 2013–2017 | ||
| GERSHELL LELAND | Officer | CFO and Treasurer; Chief Financial Officer | 16 | 2013–2015 | |
| GRACE PATRICK P | Director | 12 | 2013–2019 | ||
| LANDRY DONALD W | Director | 12 | 2013–2019 | person page Fuzzy | |
| LEDERMAN & CO., LLC | TenPercentOwner | 1 | 2013 | ||
| LEDERMAN SETH | Director,Officer; Director,Officer,TenPercentOwner; Officer | Chief Executive Officer; President and CEO | 62 | 2013–2026 | |
| MARIO ERNEST | Director | 34 | 2013–2018 | ||
| MATHER CHARLES E IV | Director | 17 | 2013–2018 | ||
| Rhodes John B | Director | 19 | 2013–2020 | ||
| Saks Samuel R | Director | 16 | 2013–2018 | ||
| KELLERMAN DONALD J | Officer | See Remarks | 3 | 2014 | |
| SULLIVAN GREGORY M | Officer | Chief Medical Officer | 29 | 2014–2026 | |
| MORRIS JESSICA EDGAR | Officer | Acting Chief Financial Officer; Chief Administrative Officer; Chief Operating Officer | 16 | 2015–2026 | |
| SAENGER BRADLEY | Officer; Officer,TenPercentOwner | Chief Financial Officer | 22 | 2016–2026 | |
| Bell Margaret Smith | Director | 12 | 2017–2026 | ||
| GRANGE DAVID L | Director | 11 | 2018–2026 | ||
| OLUKOTUN ADEOYE Y | Director | 12 | 2018–2026 | ||
| Treco James | Director | 15 | 2019–2026 | ||
| Goodman Daniel Wintner | Director | 5 | 2019–2021 | ||
| BAGGER RICHARD H | Director | 11 | 2020–2026 | person page Fuzzy | |
| Taylor Carolyn E. | Director | 9 | 2021–2026 | ||
| Stillwell Richard Newcomb | Director | 7 | 2023–2026 | ||
| Fogarty Siobhan | Officer | Chief Technology Officer | 3 | 2025–2026 | |
| Hunter James Randolph Jr | Director | 3 | 2025–2026 | ||
| Englese Thomas | Officer | Chief Commercial Officer | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2017-10-10 | Tonix Pharmaceuticals Holding Corp. | Pharmaceuticals | $15,314,798 | $314,798 | 1 | 1 |
| 2012-01-31 | Tonix Pharmaceuticals Holding Corp. | Pharmaceuticals | $10,000,000 | $4,302,950 | 81 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | TONIX PHARMACEUTICALS HOLDING CORP. | NJ | State business registries | name and state |
| Form D issuer | Tonix Pharmaceuticals Holding Corp. | NY | Form D private offerings | CIK (EXACT) |
| Lobbying client | TONIX PHARMACEUTICALS HOLDING CORP. | NJ | Federal lobbying (LDA) | name and state |
| SEC filer | Tonix Pharmaceuticals Holding Corp. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | TONIX PHARMACEUTICALS HOLDING CORP. | EIN (EXACT) | ||
| Person page | David J Moss | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer,TenPercentOwner) | |
| Person page | Donald W Landry | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Richard H Bagger | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, NJ first:
- KOS PHARMACEUTICALS INC NJ
- NOVADEL PHARMA INC NJ
- ELITE PHARMACEUTICALS INC /NV/ NJ
- MEMORY PHARMACEUTICALS CORP NJ
- PHIBRO ANIMAL HEALTH CORP NJ
- PTC THERAPEUTICS, INC. NJ
- ADVANCED NUTRACEUTICALS INC NJ
- Ayala Pharmaceuticals, Inc. NJ
- INSMED Inc NJ
- Sonnet BioTherapeutics Holdings, Inc. NJ
In other datasets, the same topic (Health) in NJ:
- Nonprofit: 1ST CEREBRAL PALSY OF NEW JERSEY INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health